Cure My Disease

Don't miss your cure!

 Log in / Sign up

A handheld device that vibrates the airways may help COPD patients breathe easier

NCT ID NCT06614959

Completed Symptom relief Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This study tests whether a device called oscillatory positive expiratory pressure (OPEP) therapy can reduce cough symptoms and improve lung mechanics in people with COPD. Participants use the device at home twice daily for four weeks. Researchers compare lung function and symptom scores before and after treatment to see if the vibrations help clear mucus and ease breathing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a handheld breathing device called oscillatory positive expiratory pressure (OPEP) therapy that creates vibrations in the airways to help clear mucus and improve lung function
What this could lead to
If it works, OPEP therapy could offer a simple, drug-free way to reduce cough burden and improve breathing mechanics for people with COPD.
What could go wrong
This is a small, single-group study with only 32 participants and no placebo control, so results may not be generalizable. The device requires daily use for 4 weeks, and adherence or discomfort could affect outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic bronchitis chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD

Contacts and locations

Locations

  • McGill University Health Centre

    Montreal, Quebec, H4A 3J1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.